Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and ...
In recent months, Anthropic has been building more and more ties with the biopharma industry, including partnerships with Big ...
Following the successful spin-off of its Sandoz generics division in late 2023, Novartis AG (NYSE:NVS) has transformed into a ...
Arrowhead Pharma (ARWR), and Novartis (NVS) are among winners of EU recommendations for their pharmaceuticals this week. Read ...
Novartis (NVS) stock is in focus as the company withdraws its bid to expand the label for its radiotherapy Pluvicto for a type of prostate cancer in the EU. Read more here.
Friday announced that the World Health Organization has prequalified Coartem® (artemether-lumefantrine) Baby, the first and ...
A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the ...
Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised. The pharma company, however, rattled the market with a decision to ...
This milestone paves the way for broader access through public sector procurement and donor-funded programs, addressing a ...
As DWTS fans know, Inaba has thick skin when it comes to dealing with difficult moments, such as being booed by audience ...
If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results